Catalyst Event
Eli Lilly and Co (LLY) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/28/2026, 12:00:00 AM
Presented positive Phase 3b data showing that combining Taltz and Zepbound was superior to Taltz alone for adults with both psoriatic arthritis and obesity.
Korean Translation
탈츠(Taltz)와 젭바운드(Zepbound) 병용 요법이 건선성 관절염과 비만을 모두 앓고 있는 성인 환자에게 탈츠 단독 요법보다 우수하다는 긍정적인 3b상 임상 데이터를 발표함.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM